New drug shows sustained benefit at 2 years in rare blood cancer
the ONA take:
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia, a rare blood cancer.
In addition, 95% of patients receiving the newly approved drug are experiencing progression-free survival 2 years after initiating treatment. When progression did occur, it began at a median of 9.6 months after the start of treatment.
Waldenstrom macroglobulinemia is caused by an abnormality in the B lymphocytes in bone marrow that causes the overproduction of IgM, an immunoglobulin protein that thickens the blood.
It is driven by the MYD88 and CXCR4 genetic mutations. MYD88 mutation triggers abnormal activity of Bruton’s tyrosine kinase. Ibrutinib targets a pathway involving Bruton’s tyrosine kinase protein.
The trial included 63 patients who had received at least one prior treatment. The drug is administered as an oral drug taken daily.
Treatment continued until the disease worsened or unacceptable toxic effects occurred. Response rate in the study refers to the degree of reduction in IgM in the blood.
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|